Multiple sclerosis: assay of free immunoglobulin light chains

Annals of Clinical Biochemistry

Volumn 54, Issue 1, 2017, Pages 5-13

  Ramsden, D B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Analytical systems; clinical studies; immunoassay; laboratory methods; neurological disorders

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; BIOASSAY; LIMIT OF DETECTION; PATHOLOGY;

BIOLOGICAL ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; LIMIT OF DETECTION; MULTIPLE SCLEROSIS;

EID: 85006778804     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563216652175     Document Type: Review

References (56)

1. Sandberg-Wollheim M, Zettervall O. In vitro synthesis of IgG by cells from the cerebrospinal fluid in a patient with multiple sclerosis. Clin Exp Immunol 1969; 4: 401–405.
2. McDonald WI, Compston A, Edan G. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.
3. Polman CH, Reingold SC, Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”. Ann Neurol 2005; 58: 840–846.
4. Polman CH, Reingold SC, Banwell B. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
5. Rovira À, Wattjes MP, Tintoré M. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 2015; 11: 471–482.
6. MAGNIMS study group; Wattjes MP, Rovira À, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11: 597–606
7. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987; 163: 319–328.
8. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4: 111–117.
9. Link H. Immunoglobulin G and low molecular weight proteins in human cerebrospinal fluid. Chemical and immunological characterization with special reference to multiple sclerosis. Acta Neurol Scand 1967; 43(Suppl 28): l–136.
10. Bracco F, Gallo P, Menna R. Free light chains in the CSF in multiple sclerosis. J Neurol 1987; 234: 303–307.
11. DeCarli C, Menegus MA, Rudick RA. Free light chains in multiple sclerosis and infections of the CNS. Neurol 1987; 37: 1334–1338.
12. Fagnart OC, Sindic CJM, Laterre C. Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J Neuroimmunol 1988; 19: 119–132.
13. Stanescu GL, Swick AR, Tuohy VK. Sensitive competitive-binding ELISAs for quantifying free kappa and lambda light chains in cerebrospinal fluid. J Clin Lab Anal 1991; 5: 206–211.
14. Rudick RA, Pallant A, Bidlack JM. Free kappa light chains in multiple sclerosis spinal fluid. Ann Neurol 1986; 20: 63–69.
15. Lolli F, Siracusa G, Amato MP. Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis. Acta Neurol Scand 1991; 83: 239–243.
16. Bradwell AR, Carr-Smith HD, Mead GP. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673–680.
17. Drayson M, Tang LX, Drew R. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900–2902.
18. Abraham RS, Katzmann JA, Clark RJ. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274–278.
19. Hutchison CA, Burmeister A, Harding SJ. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease. Mayo Clin Proc 2014; 89: 615–622.
20. Senel M, Tumani H, Lauda F. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. Plos One 2014; 9: 1–7.
21. Desplat-jégo S, Feuillet L, Pelletier J. Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J Clin Immunol 2005; 25: 338–345.
22. Makshakov G, Nazarov V, Kochetova O. Diagnostic and prognostic value of the cerebrospinal fluid concentration of immunoglobulin free light chains in clinically isolated syndrome with conversion to multiple sclerosis. PLoS One 2015; 10: e0143375.
23. Hassan-Smith G, Durant L, Tsentemeidou A. High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol 2014; 276: 175–179.
24. Kaplan B, Golderman S, Yahalom G. Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis. J Immunol Methods 2013; 390: 74–80.
25. Fischer C, Arneth B, Koehler J. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin Chem 2004; 50: 1809–1813.
26. Arneth B, Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009; 119: 39–44.
27. Zeman D, Kušnierová P, Bartoš V. Quantitation of free light chains in the cerebrospinal fluid reliably predicts their intrathecal synthesis. Ann Clin Biochem 2016; 53: 174–176.
28. Presslauer S, Milosavljevic D, Hübl W. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study. Mult Scler 2015; 22: 502–510.
29. Bernardi G, Cataldo I. La determinazione delle catene leggere libere nel liquido cefalorachidiano: l'esperienza di due laboratori Italiani. Biochim Clin 2013; 37: 389–394.
30. Presslauer S, Milosavljevic D, Brücke T. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008; 255: 1508–1514.
31. Goffette S, Schluep M, Henry H. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 308–310.
32. Dobson R, Ramagopalan S, Davis A. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84: 909–914.
33. Kuhle J, Hardmeier M, Disanto G. European long-term follow-up study group in interferon β-1b in secondary-progressive multiple sclerosis. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Mult Scler 2015; 22: 533–543.
34. Tintore M, Rovira A, Rıo J. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138: 1863–1874.
35. Villar LM, Espiño M, Costa-Frossard L. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin Chim Acta 2012; 413: 1813–1816.
36. Presslauer S, Milosavljevic D, Hübl W. Kappa free light chains: diagnostic and prognostic relevance in MS and CIS. Plos One 2014; 9: 1–6.
37. Becker M, Latarche C, Roman E. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol 2015; 15: 79.
38. Anagnostouli M, Christidi F, Zalonis I. Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients. Neurol Sci 2015; 36: 2053–2060.
39. Rudick RA, Medendorp SV, Namey M. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995; 1: 150–155.
40. Rinker JR, II Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006; 67: 1288–1290.
41. Rudick RA, Cookfair DL, Simonian NA. Cerebrospinal fluid abnormalities in a phase III trial of Avonex IFNb-1a for relapsing multiple sclerosis. J Neuroimmunol 1999; 93: 8–14.
42. Zemana D, Hradilek P, Kusnierova P. Oligoclonal free light chains in cerebrospinal fluid as markers of intrathecal inflammation. Comparison with oligoclonal IgG. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 15: 104–113.
43. Bonnan M. Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int 2015; 2015: 296184.
44. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003; 21: 79–96.
45. Rudick RA, French CA, Breton D. Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests. Neurology 1989; 39: 964–968.
46. Mehta PD, Cook SD, Troiano RA. Increased free light chains in the urine from patients with multiple sclerosis. Neurology 1991; 41: 540–544.
47. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4: 111–117.
48. Housley WJ, Pitt D, Hafler DA. Biomarkers in multiple sclerosis. Clin Immunol 2015; 161: 51–58.
49. D'Ambrosio A, Pontecorvo S, Colasanti T. Peripheral blood biomarkers in multiple sclerosis. Autoimmun Rev 2015; 14: 1097–1110.
50. Giorgio A, Battaglini M, Rocca MA. Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology 2013; 80: 234–241.
51. Popescu V, Agosta F, Hulst HE. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082–1091.
52. Gass A, Rocca MA, Agosta F. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol 2015; 14: 443–454.
53. Rocca MA, Amato MP, De Stefano N. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 2015; 14: 302–317.
54. Vrenken H, Jenkinson M, Horsfield MA. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013; 260: 2458–2471.
55. Abbasian Ardakani A, Gharbali A, Saniei Y. Application of texture analysis in diagnosis of multiple sclerosis by magnetic resonance imaging. Glob J Health Sci 2015; 7: 68–78.
56. Duranti F, Pieri M, Centonze D. Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. J Neuroimmunol 2013; 263: 116–120.